RSV is a common and highly contagious respiratory virus that is a leading cause of lung disease. RSV is seasonal, and like other respiratory viruses, its peak incidence is during the winter months each year. It spreads from person to person via droplets, or from infected surfaces or objects. RSV is a virus, so antibiotics are not effective.
Arexvy is a new vaccination designed to protect against lower respiratory tract disease caused by respiratory syncytial virus (RSV). It is an important advance, because no specific treatment for RSV is available, and infection is often severe.
Older adults, and those with underlying medical conditions such as diabetes, heart disease and lung diseases such as asthma and COPD are at the greatest risk of the infection. RSV can exacerbate these underlying conditions and lead to pneumonia.
In the UK, RSV causes more hospitalisations and deaths than flu in those over the age of 60. It is estimated that RSV causes14,000 hospitalisations and an estimated 8,000 deaths in adults 60 years of age and older each year.
Arexvy is a recombinant adjuvanted vaccine for the prevention of RSV is adults 60 years of age and above. It is the only licensed vaccination in the UK that has been authorised for use by the Medicines and Healthcare products Regulatory Agency, meaning at risk adults are now able to be vaccinated against the disease.
Arexvy is as in inactive vaccination and only requires single dose for protection. It can be administered at the same time as other vaccinations including flu, pneumococcal, and COVID.
We are among the first practices in the UK to offer it to adults needing protection.